ASCO GU 2021: Discussant: Enfortumab Vedotin (EV) in Previously Treated Urothelial Cancer – Results of EV-301 & EV-201 Cohort 2
(UroToday.com) She first reviewed the results of EV-301 (Abstract 393) which provided level 1 evidence of overall survival benefit with EV compared to single-agent chemotherapy in patients who progressed on platinum chemotherapy and immune checkpoint blockade. The trial schema and relevant overall survival data are re-shown below. EV also demonstrated a progression-free survival benefit and improved […]